{
    "hands_on_practices": [
        {
            "introduction": "To ground our understanding of reimbursement models, we begin with the fundamental concept of value-based pricing. A central question for any payer is: what is a fair price for a new genomic test? This practice guides you through a core calculation using the Net Monetary Benefit (NMB) framework to determine a test's \"break-even\" price—the point at which its cost is perfectly balanced by the monetized value of its health benefits and downstream cost savings. Mastering this calculation  is essential for understanding how payers establish a rational basis for reimbursement negotiations.",
            "id": "4377291",
            "problem": "A national payer is evaluating reimbursement for a new comprehensive genomic profiling test used to guide targeted therapy selection in oncology. From the payer perspective over a one-year horizon, the test produces an expected incremental health gain of $\\Delta Q = 0.015$ Quality-Adjusted Life Years (QALYs), where Quality-Adjusted Life Year (QALY) is defined in the conventional health economic sense. The test also produces expected downstream medical cost savings of $\\$1{,}800$ per tested patient due to avoided ineffective therapies and reduced adverse event management. Let the unit test price be $\\$P$, fully reimbursed by the payer. The payer uses a willingness-to-pay threshold of $\\lambda = \\$100{,}000$ per QALY.\n\nUnder the Net Monetary Benefit (NMB) framework, where Net Monetary Benefit (NMB) represents the monetized health gain minus the incremental costs from the payer perspective, assume that all quantities are in expected values, already discounted where appropriate, and that the only incremental costs are the test price and the downstream savings as stated above.\n\nDetermine the break-even unit price $\\$P^{\\ast}$ such that the net monetary benefit equals zero for a single tested patient. Express your answer in United States dollars (USD) as an exact value with no rounding.",
            "solution": "The problem requires the determination of a break-even price for a genomic test based on the Net Monetary Benefit (NMB) framework from a payer's perspective.\n\n### Step 1: Extract Givens\nThe data and definitions provided in the problem statement are:\n- Incremental health gain: $\\Delta Q = 0.015$ Quality-Adjusted Life Years (QALYs).\n- Downstream medical cost savings: $C_{savings} = \\$1,800$.\n- Unit test price: $P$.\n- Payer's willingness-to-pay threshold: $\\lambda = \\$100,000$ per QALY.\n- Framework: Net Monetary Benefit (NMB).\n- Definition of NMB: Monetized health gain minus incremental costs.\n- Condition for break-even price $P^{\\ast}$: $NMB = 0$.\n\n### Step 2: Validate Using Extracted Givens\nThe problem is validated against the specified criteria:\n- **Scientifically Grounded**: The problem is based on standard, well-established principles of health economics, specifically cost-effectiveness analysis using the Net Monetary Benefit framework. Key concepts like QALYs, willingness-to-pay thresholds, and payer-perspective economic evaluation are used correctly and are fundamental to the field of health technology assessment. The values provided are realistic for such an evaluation.\n- **Well-Posed**: The problem is clearly defined. It specifies a formula for NMB and asks to solve for a single variable, $P^{\\ast}$, under the condition $NMB=0$. All necessary information is provided to derive a unique solution.\n- **Objective**: The problem is stated in precise, quantitative, and unbiased language. It is free of subjective claims.\n- **Completeness and Consistency**: The problem is self-contained. It provides all variables and relationships needed for the calculation ($\\Delta Q$, $\\lambda$, $C_{savings}$) and contains no contradictory information. The assumptions (e.g., expected values, costs considered) are explicitly stated.\n- **Relatedness to Topic**: The problem is directly and correctly situated within the specified topic of *reimbursement policies and economic models for genomic testing* in the field of *precision medicine and genomic diagnostics*.\n\nThe problem is deemed valid as it is a well-posed, scientifically grounded, and objective application of a standard economic model.\n\n### Step 3: Solve the Valid Problem\nThe Net Monetary Benefit (NMB) is an approach to value health outcomes and costs in a common monetary unit. It is defined as the monetized value of the health gain minus the incremental net cost.\n\nThe monetized value of the health gain is the incremental health gain, $\\Delta Q$, multiplied by the societal or payer's willingness-to-pay for that gain, $\\lambda$.\n$$ \\text{Monetized Health Gain} = \\lambda \\times \\Delta Q $$\n\nThe incremental cost from the payer's perspective is the new cost incurred minus any cost savings. The new cost is the price of the test, $P$. The cost savings are given as $C_{savings}$.\n$$ \\text{Incremental Net Cost} = P - C_{savings} $$\n\nTherefore, the NMB equation is:\n$$ NMB = (\\lambda \\times \\Delta Q) - (P - C_{savings}) $$\n\nThe problem asks for the break-even unit price, $P^{\\ast}$, at which the Net Monetary Benefit is zero. We set $NMB = 0$ and solve for $P=P^{\\ast}$.\n$$ 0 = (\\lambda \\times \\Delta Q) - (P^{\\ast} - C_{savings}) $$\n\nRearranging the equation to solve for $P^{\\ast}$:\n$$ P^{\\ast} - C_{savings} = \\lambda \\times \\Delta Q $$\n$$ P^{\\ast} = (\\lambda \\times \\Delta Q) + C_{savings} $$\n\nNow, we substitute the given values into this equation:\n- $\\lambda = 100,000$ (in USD per QALY)\n- $\\Delta Q = 0.015$ (in QALYs)\n- $C_{savings} = 1,800$ (in USD)\n\nFirst, calculate the monetized health gain:\n$$ \\lambda \\times \\Delta Q = 100,000 \\times 0.015 = 1,500 $$\nThis result is in units of USD.\n\nNext, add the cost savings to find the break-even price $P^{\\ast}$:\n$$ P^{\\ast} = 1,500 + 1,800 $$\n$$ P^{\\ast} = 3,300 $$\n\nThus, the break-even unit price for the test, from the payer's perspective, is $\\$3,300$. At this price, the cost of the test is exactly offset by the sum of the monetized health benefits and the downstream cost savings, resulting in a Net Monetary Benefit of zero.",
            "answer": "$$\n\\boxed{3300}\n$$"
        },
        {
            "introduction": "The value of a diagnostic test is not just in its potential health benefits, but also in its accuracy. A test's sensitivity and specificity directly influence clinical decisions and have significant economic repercussions, particularly from managing incorrect results. This exercise  delves into this critical link by tasking you to calculate the Positive and Negative Predictive Values (PPV and NPV) and, crucially, the expected costs a payer incurs from unnecessary follow-up procedures due to false-positive results. This practice highlights how test performance in a specific population shapes its overall economic profile.",
            "id": "4377402",
            "problem": "Consider a single-gene genomic assay deployed in a clinically enriched cohort for precision oncology. Let disease status be a Bernoulli random variable with prevalence $\\pi = 0.05$. The assay has sensitivity $Se = 0.90$ and specificity $Sp = 0.95$. A health plan reimburses the assay and requires a confirmatory diagnostic procedure following any positive assay result. The confirmatory diagnostic is reimbursed at a fixed cost $C = 1000$ dollars per procedure. Assume confirmatory diagnostics are performed for all initial positive assay results and that confirmatory diagnostics following false positive assay results are clinically unnecessary but still reimbursed.\n\nUsing only the law of total probability and Bayes’ theorem, and starting from the core definitions $Se = \\mathbb{P}(T^{+}\\mid D^{+})$, $Sp = \\mathbb{P}(T^{-}\\mid D^{-})$, and prevalence $\\pi = \\mathbb{P}(D^{+})$, derive expressions for the Positive Predictive Value (PPV) and Negative Predictive Value (NPV) of the assay in terms of $Se$, $Sp$, and $\\pi$, and then evaluate them at $Se = 0.90$, $Sp = 0.95$, and $\\pi = 0.05$. Next, derive an expression for the expected payer expenditure on clinically unnecessary confirmatory diagnostics per tested individual, and evaluate it at the given parameter values and $C = 1000$ dollars.\n\nExpress PPV and NPV as decimals. Express the expected expenditure as dollars. Round all requested numerical values to four significant figures.",
            "solution": "The problem is well-posed and scientifically grounded, providing all necessary information to derive the requested quantities using standard principles of probability theory. We proceed with the solution.\n\nLet $D^{+}$ denote the event that an individual has the disease, and $D^{-}$ denote the event that the individual does not have the disease. Let $T^{+}$ be the event of a positive assay result and $T^{-}$ be the event of a negative assay result.\n\nThe given parameters are:\n- Prevalence of the disease, $\\pi = \\mathbb{P}(D^{+}) = 0.05$.\n- Probability of not having the disease, $\\mathbb{P}(D^{-}) = 1 - \\pi = 1 - 0.05 = 0.95$.\n- Sensitivity of the assay, $Se = \\mathbb{P}(T^{+} \\mid D^{+}) = 0.90$.\n- Specificity of the assay, $Sp = \\mathbb{P}(T^{-} \\mid D^{-}) = 0.95$.\n- Cost of a confirmatory diagnostic procedure, $C = 1000$ dollars.\n\nFrom the definitions of sensitivity and specificity, we can derive the false negative and false positive rates:\n- False Negative Rate: $\\mathbb{P}(T^{-} \\mid D^{+}) = 1 - Se = 1 - 0.90 = 0.10$.\n- False Positive Rate: $\\mathbb{P}(T^{+} \\mid D^{-}) = 1 - Sp = 1 - 0.95 = 0.05$.\n\n**1. Derivation and Calculation of Positive Predictive Value (PPV)**\n\nThe Positive Predictive Value (PPV) is the probability that an individual has the disease given a positive test result, defined as $PPV = \\mathbb{P}(D^{+} \\mid T^{+})$.\n\nUsing Bayes' theorem:\n$$PPV = \\mathbb{P}(D^{+} \\mid T^{+}) = \\frac{\\mathbb{P}(T^{+} \\mid D^{+}) \\mathbb{P}(D^{+})}{\\mathbb{P}(T^{+})}$$\n\nThe denominator, $\\mathbb{P}(T^{+})$, is the total probability of a positive test result. We find it using the law of total probability:\n$$\\mathbb{P}(T^{+}) = \\mathbb{P}(T^{+} \\mid D^{+})\\mathbb{P}(D^{+}) + \\mathbb{P}(T^{+} \\mid D^{-})\\mathbb{P}(D^{-})$$\nSubstituting the known terms ($Se$, $Sp$, $\\pi$):\n$$\\mathbb{P}(T^{+}) = (Se)(\\pi) + (1 - Sp)(1 - \\pi)$$\n\nSubstituting this expression for $\\mathbb{P}(T^{+})$ back into the formula for PPV gives the expression in terms of the given parameters:\n$$PPV = \\frac{Se \\cdot \\pi}{Se \\cdot \\pi + (1 - Sp)(1 - \\pi)}$$\n\nNow, we evaluate this expression with the given numerical values:\n$$PPV = \\frac{0.90 \\cdot 0.05}{0.90 \\cdot 0.05 + (1 - 0.95)(1 - 0.05)} = \\frac{0.045}{0.045 + (0.05)(0.95)} = \\frac{0.045}{0.045 + 0.0475} = \\frac{0.045}{0.0925}$$\n$$PPV \\approx 0.486486...$$\nRounding to four significant figures, we get $PPV = 0.4865$.\n\n**2. Derivation and Calculation of Negative Predictive Value (NPV)**\n\nThe Negative Predictive Value (NPV) is the probability that an individual does not have the disease given a negative test result, defined as $NPV = \\mathbb{P}(D^{-} \\mid T^{-})$.\n\nUsing Bayes' theorem:\n$$NPV = \\mathbb{P}(D^{-} \\mid T^{-}) = \\frac{\\mathbb{P}(T^{-} \\mid D^{-}) \\mathbb{P}(D^{-})}{\\mathbb{P}(T^{-})}$$\n\nThe denominator, $\\mathbb{P}(T^{-})$, is the total probability of a negative test result. We find it using the law of total probability:\n$$\\mathbb{P}(T^{-}) = \\mathbb{P}(T^{-} \\mid D^{-})\\mathbb{P}(D^{-}) + \\mathbb{P}(T^{-} \\mid D^{+})\\mathbb{P}(D^{+})$$\nSubstituting the known terms ($Se$, $Sp$, $\\pi$):\n$$\\mathbb{P}(T^{-}) = (Sp)(1 - \\pi) + (1 - Se)(\\pi)$$\n\nSubstituting this expression for $\\mathbb{P}(T^{-})$ back into the formula for NPV gives the expression in terms of the given parameters:\n$$NPV = \\frac{Sp \\cdot (1 - \\pi)}{Sp \\cdot (1 - \\pi) + (1 - Se)\\pi}$$\n\nNow, we evaluate this expression with the given numerical values:\n$$NPV = \\frac{0.95 \\cdot (1 - 0.05)}{0.95 \\cdot (1 - 0.05) + (1 - 0.90)(0.05)} = \\frac{0.95 \\cdot 0.95}{0.95 \\cdot 0.95 + 0.10 \\cdot 0.05} = \\frac{0.9025}{0.9025 + 0.005} = \\frac{0.9025}{0.9075}$$\n$$NPV \\approx 0.994490...$$\nRounding to four significant figures, we get $NPV = 0.9945$.\n\n**3. Derivation and Calculation of Expected Expenditure on Unnecessary Diagnostics**\n\nThe expected payer expenditure on clinically unnecessary confirmatory diagnostics, let's call it $E$, is the cost of such a diagnostic multiplied by the probability of it occurring for a randomly tested individual. An unnecessary confirmatory diagnostic is performed following a false positive result. A false positive event is the joint occurrence of a positive test ($T^{+}$) and the absence of disease ($D^{-}$).\n\nWe need to find the probability of this joint event, $\\mathbb{P}(T^{+} \\cap D^{-})$. Using the definition of conditional probability:\n$$\\mathbb{P}(T^{+} \\cap D^{-}) = \\mathbb{P}(T^{+} \\mid D^{-}) \\mathbb{P}(D^{-})$$\nThis probability is also known as the false positive rate for the population.\nSubstituting the known terms:\n$$\\mathbb{P}(T^{+} \\cap D^{-}) = (1 - Sp)(1 - \\pi)$$\n\nThe expected expenditure $E$ is the cost $C$ of the procedure multiplied by this probability:\n$$E = C \\cdot \\mathbb{P}(T^{+} \\cap D^{-}) = C \\cdot (1 - Sp) \\cdot (1 - \\pi)$$\n\nNow, we evaluate this expression with the given numerical values, $C = 1000$, $Sp = 0.95$, and $\\pi = 0.05$:\n$$E = 1000 \\cdot (1 - 0.95) \\cdot (1 - 0.05) = 1000 \\cdot (0.05) \\cdot (0.95)$$\n$$E = 1000 \\cdot 0.0475 = 47.5$$\nThe problem requires rounding to four significant figures, so the expenditure is $47.50$ dollars.\n\nThe three requested values are PPV, NPV, and the expected expenditure.",
            "answer": "$$\\boxed{\\begin{pmatrix} 0.4865 & 0.9945 & 47.50 \\end{pmatrix}}$$"
        },
        {
            "introduction": "Reimbursement decisions are often made with incomplete evidence, creating uncertainty about a new technology's true value. This final practice addresses this challenge by introducing a powerful concept from decision theory: the Expected Value of Perfect Information (EVPI). By working through this hypothetical scenario , you will quantify the maximum value of obtaining perfect information to resolve uncertainty before committing to a coverage decision. This analysis helps payers determine whether it is more valuable to adopt a technology now or to invest in further research.",
            "id": "4377284",
            "problem": "A national payer is evaluating whether to reimburse a comprehensive genomic profiling test for advanced non-small cell lung cancer within a precision oncology program. The payer uses the Net Monetary Benefit (NMB) framework at a fixed willingness-to-pay threshold, where the option implemented under uncertainty is the one that maximizes expected value. The standard of care without the genomic test is the baseline with $NMB$ equal to $0$. Based on current evidence synthesis, the clinical utility of the test is uncertain and takes one of two states: effective or ineffective. If the test is effective, the incremental $NMB$ of adopting the test versus not adopting it is $3{,}000$. If the test is ineffective, the incremental $NMB$ is $-1{,}000$. The payer’s current belief assigns probability $0.6$ to the test being effective and probability $0.4$ to it being ineffective. Under perfect information, the payer can condition the adoption decision on the realized state of clinical utility.\n\nUsing only the definitions of rational choice under uncertainty in cost-effectiveness analysis (maximize expected $NMB$ under current evidence) and the notion that perfect information allows state-contingent choice prior to implementation, determine the Expected Value of Perfect Information (EVPI) for the single decision of whether to reimburse the genomic test. Provide the exact value in United States dollars (USD). Do not round.",
            "solution": "The problem asks for the determination of the Expected Value of Perfect Information (EVPI) for a decision concerning the reimbursement of a genomic test. The EVPI quantifies the maximum value a decision-maker should be willing to pay for information that would resolve all uncertainty about the states of nature before a decision is made. It is calculated as the difference between the expected value of a decision made with perfect information and the expected value of the optimal decision made under uncertainty.\n\nLet the two states of nature be $S_{\\text{eff}}$, where the test is effective, and $S_{\\text{ineff}}$, where the test is ineffective.\nThe prior probabilities for these states are given as:\n$P(S_{\\text{eff}}) = 0.6$\n$P(S_{\\text{ineff}}) = 0.4$\n\nThe decision-maker has two possible actions: $A_{\\text{adopt}}$, to adopt and reimburse the test, and $A_{\\neg\\text{adopt}}$, to not adopt the test (maintain the standard of care).\n\nThe problem provides the incremental Net Monetary Benefit (NMB) for adopting the test compared to not adopting it for each state of nature. The incremental NMB of not adopting the test is, by definition, $0$. Let $NMB(A, S)$ denote the incremental NMB of action $A$ in state $S$.\n\nThe given payoffs are:\n$NMB(A_{\\text{adopt}}, S_{\\text{eff}}) = 3000$ USD\n$NMB(A_{\\text{adopt}}, S_{\\text{ineff}}) = -1000$ USD\n$NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}}) = 0$ USD\n$NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}}) = 0$ USD\n\nFirst, we determine the optimal decision under current uncertainty. This is the action that maximizes the Expected Net Monetary Benefit (ENMB).\n\nThe ENMB for adopting the test is:\n$$ENMB(A_{\\text{adopt}}) = P(S_{\\text{eff}}) \\times NMB(A_{\\text{adopt}}, S_{\\text{eff}}) + P(S_{\\text{ineff}}) \\times NMB(A_{\\text{adopt}}, S_{\\text{ineff}})$$\n$$ENMB(A_{\\text{adopt}}) = (0.6) \\times (3000) + (0.4) \\times (-1000)$$\n$$ENMB(A_{\\text{adopt}}) = 1800 - 400 = 1400 \\text{ USD}$$\n\nThe ENMB for not adopting the test is:\n$$ENMB(A_{\\neg\\text{adopt}}) = P(S_{\\text{eff}}) \\times NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}}) + P(S_{\\text{ineff}}) \\times NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}})$$\n$$ENMB(A_{\\neg\\text{adopt}}) = (0.6) \\times (0) + (0.4) \\times (0) = 0 \\text{ USD}$$\n\nTo find the optimal decision under uncertainty, we compare the ENMB of the two actions:\n$$ENMB_{\\text{max}} = \\max(ENMB(A_{\\text{adopt}}), ENMB(A_{\\neg\\text{adopt}})) = \\max(1400, 0) = 1400 \\text{ USD}$$\nSince $1400 > 0$, the optimal decision under uncertainty is to adopt the test ($A_{\\text{adopt}}$). The expected value of this optimal decision is $1400$ USD.\n\nNext, we calculate the Expected Value with Perfect Information (EVwPI). With perfect information, the decision-maker would know the true state of nature before choosing an action. They would choose the action that maximizes the NMB for that specific state.\n\nIf the true state is $S_{\\text{eff}}$, the optimal action is the one that gives the higher NMB:\n$$\\max(NMB(A_{\\text{adopt}}, S_{\\text{eff}}), NMB(A_{\\neg\\text{adopt}}, S_{\\text{eff}})) = \\max(3000, 0) = 3000 \\text{ USD}$$\nSo, if the test is known to be effective, the decision-maker would adopt it.\n\nIf the true state is $S_{\\text{ineff}}$, the optimal action is:\n$$\\max(NMB(A_{\\text{adopt}}, S_{\\text{ineff}}), NMB(A_{\\neg\\text{adopt}}, S_{\\text{ineff}})) = \\max(-1000, 0) = 0 \\text{ USD}$$\nSo, if the test is known to be ineffective, the decision-maker would not adopt it.\n\nThe EVwPI is the expected value of these state-contingent optimal decisions, weighted by the prior probabilities of the states occurring:\n$$EVwPI = P(S_{\\text{eff}}) \\times \\max(3000, 0) + P(S_{\\text{ineff}}) \\times \\max(-1000, 0)$$\n$$EVwPI = (0.6) \\times (3000) + (0.4) \\times (0)$$\n$$EVwPI = 1800 + 0 = 1800 \\text{ USD}$$\n\nFinally, the EVPI is the difference between the Expected Value with Perfect Information and the maximum Expected Net Monetary Benefit under uncertainty:\n$$EVPI = EVwPI - ENMB_{\\text{max}}$$\n$$EVPI = 1800 - 1400 = 400 \\text{ USD}$$\n\nThe EVPI represents the expected gain from avoiding the consequences of making a suboptimal choice. The suboptimal choice occurs when adopting the test ($A_{\\text{adopt}}$) if the state is actually $S_{\\text{ineff}}$. The loss from this error, or \"opportunity loss,\" is the value of the best action in that state minus the value of the chosen action: $0 - (-1000) = 1000$. This error occurs with probability $P(S_{\\text{ineff}}) = 0.4$. The expected opportunity loss is thus $0.4 \\times 1000 = 400$, which is the EVPI.",
            "answer": "$$\\boxed{400}$$"
        }
    ]
}